Regeneron (REGN) Gains Attention With Successful Phase 3 Garetosmab Trial for Rare Disease

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most undervalued NASDAQ stocks to buy now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported on September 17 that its experimental medicine garetosmab has met the primary endpoint in a phase 3 trial for adults with fibrodysplasia ossificans progressiva, a rare genetic condition in which muscles, tendons, and ligaments gradually convert into bone.

According to the OPTIMA trial, at 56 weeks, both garetosmab dosages decreased new bone lesions by 90% or more when compared to a placebo.

An Independent Data Monitoring Committee advised switching placebo patients to garetosmab medication immediately based on the safety profile and results. By the end of 2025, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) aims to submit the medication for regulatory approval in the US, with global submissions expected for the year after.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a prominent biopharmaceutical company that discovers, develops, and commercializes medicines for a variety of diseases, including cancer, eye disorders, and allergies.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.